NEW YORK — Patients taking lower doses of metformin may be at lower risk for age-related macular degeneration, revealing a potential novel therapy strategy, according to a speaker at the American Society of Retina Specialists meeting.
Dimitra Skondra, MD, PhD, said metformin has been getting a lot of attention as a potential way to address the “holy grail” of medicine, aging.
“Patients on metformin have decreased morbidity in cancer, heart disease and cognitive function,” she said. “What about AMD, the aging disease of the eye? When we see the pathway that